Nirvana Life Sciences Inc

As of January 31, 2026, Nirvana Life Sciences Inc carries a market capitalization of 1.60M, placing it among publicly traded companies globally. Its enterprise value stands at 1.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of January 31, 2026, Nirvana Life Sciences Inc has 22.82M shares outstanding.

These figures are as of January 31, 2026.

As of January 31, 2026, Nirvana Life Sciences Inc maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -20.05, indicating conservative leverage, while an interest coverage ratio of -164.94 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended January 31, 2026. Return on assets (ROA) is negative at -1,720.07, reflecting losses generated across the asset base.

As of the close on August 31, 2026, Nirvana Life Sciences Inc's stock has declined approximately 37.50% over the past 52 weeks. The 50-day moving average sits at 0.63, while the 200-day moving average is 4.19.

Over the twelve months ended January 31, 2026, Nirvana Life Sciences Inc generated - - in revenue and converted that into -350,534.00 in net income, yielding earnings per share of -0.02. EBITDA reached -329,887.00, while operating income came in at -343,887.00.

As of January 31, 2026, Nirvana Life Sciences Inc holds 1,347.00 in cash and equivalents against 142,173.00 in total debt, resulting in a net debt position of 140,826.00. Total book value stands at -703,921.00, with working capital of -622,947.00 providing operational flexibility.

Nirvana Life Sciences Inc produced -880,322.00 in operating cash flow over the twelve months ended January 31, 2026.

Over the twelve months ended January 31, 2026, Nirvana Life Sciences Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -68.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 64.95, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Nirvana Life Sciences Inc shareholders.

Nirvana Life Sciences Inc's most recent stock split took place on March 25, 2025 with a 10:1 split ratio.

As of January 31, 2026, Nirvana Life Sciences Inc has an Altman Z-Score of -722.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.